Protagonist Therapeutics, Inc.
PTGX
$44.27
-$1.00-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -105.62% | 381.70% | 2.62% | 20.40% | 714.80% |
| Total Depreciation and Amortization | -1.46% | -35.58% | -21.77% | 8.65% | -1.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.87% | 20.56% | 27.23% | -1.37% | 18.61% |
| Change in Net Operating Assets | 151.24% | -918.96% | -389.32% | 7,144.00% | -2,950.34% |
| Cash from Operations | 557.05% | -272.04% | -4.70% | 1,123.79% | 20.14% |
| Capital Expenditure | -125.21% | -1,531.58% | -91.83% | 84.09% | -2,320.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,586.73% | 86.27% | -1,480.65% | -439.62% | -35.82% |
| Cash from Investing | -1,654.97% | 85.76% | -1,439.27% | -442.05% | -38.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 52.87% | 664.90% | -65.88% | -97.64% | -70.64% |
| Repurchase of Common Stock | 20.17% | -- | -- | 100.00% | -500.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 58.95% | 664.90% | -65.88% | -97.62% | -72.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 399.48% | 22.67% | -4,524.55% | 69.99% | -829.09% |